Orion and Aitia Join Forces for AI-Based Drug Discovery and Drug Simulation in Oncology
Shots:
- Orion Corporation and Aitia have entered into a partnership to develop Gemini Digital Twins using Causal AI technology for cancer treatment
- Both the companies will together discover and validate novel cancer drug targets using Aitia's Digital Twins and Orion's pre-clinical & clinical data as well as expertise. Orion gains an exclusive option to research, develop & commercialize products targeting these discoveries
- Aitia will get a total of >$10M per drug target incl. upfront, development & regulatory milestones, plus additional tiered single-digit sales-based royalties
Ref: Orion | Image: Orion & Aitia
Related News:- Orion Signs a Collaborative Agreement with Newel Health to Develop ODD-403 for Chronic Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
